December 7, 2023 07:15 AM ESTUpdated 07:28 AM
R&D

Mer­ck de­tails PhII TIG­IT/PD-1 fail in lung can­cer

Amber Tong

Nine months af­ter re­veal­ing that its TIG­IT/PD-1 com­bo failed a mid-stage lung can­cer study, Mer­ck is spelling out the full re­sults — with the com­bo miss­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times